Pliant Therapeutics

Pliant Therapeutics company information, Employees & Contact Information

Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients. We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates. Pliant is an equal opportunity employer and does not discriminate against any individual or potential candidate based on race, color, religion, sex, national origin, sexual preference or any other legally protected category. Pliant is located in South San Francisco, California, the birthplace of biotechnology. Learn more about how we are the leader in the discovery and development of integrin-based therapeutic at www.PliantRx.com.

Company Details

Employees
143
Founded
-
Address
331 Oyster Point Blvd, South San Francisco,california 94080,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Pliant Therapeutics employee's phone or email?

Pliant Therapeutics Questions

News

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - GlobeNewswire

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis GlobeNewswire

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - Yahoo Finance

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Yahoo Finance

Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis - PR Newswire

Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis PR Newswire

EX-99.1 - SEC.gov

EX-99.1 SEC.gov

Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data - Stock Titan

Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data Stock Titan

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations GlobeNewswire

Treatment for Primary Sclerosing Cholangitis Gets Orphan Drug Status - Medical Professionals Reference

Treatment for Primary Sclerosing Cholangitis Gets Orphan Drug Status Medical Professionals Reference

Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases - PR Newswire

Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases PR Newswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 GlobeNewswire

Top Pliant Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant